Verrica is advancing its lead product VP-102, a proprietary topical therapy, in many common skin indications including molluscum contagiosum and verruca vulgaris (common warts). Our lead product VP-102 is a topical that is applied directly to the lesions. VP-102 is designed to be convenient for both patients and practitioners. Verrica is also pursuing additional common dermal indications. We have two on-going Phase 3 trials in patients with molluscum contagiosum under NCT03377803 (CAMP 2) and NCT03377790 (CAMP 1).